adrogolide hydrochloride

the diacetyl prodrug of A-86929; structure given in first source

Also Known As:

ABT 431; ABT-431

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - adrogolide hydrochloride: 5
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Tetrahydronaphthalenes: 1
        adrogolide hydrochloride: 5
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - adrogolide hydrochloride: 5

Experts

1.	Blin, O: 1 article (02/2001)
2.	Carter, J H: 1 article (02/2001)
3.	Currie, L J: 1 article (02/2001)
4.	Fabre, N: 1 article (02/2001)
5.	Giardina, W W: 1 article (02/2001)
6.	Goetz, C G: 1 article (02/2001)
7.	Nutt, J G: 1 article (02/2001)
8.	Rascol, O: 1 article (02/2001)
9.	Soubrouillard, C: 1 article (02/2001)
10.	Thalamas, C: 1 article (02/2001)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/1996 - "A-86929 and ABT-431 improved behavioral disability scores and increased locomotor activity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned marmoset model of Parkinson's disease in a dose-dependent manner (the minimum effective dose was 0.10 mumol/kg s.c.). " 06/01/1999 - "Assuming that ABT-431 is not transformed in humans into an unknown active D2 metabolite, and remains selective for D1 receptors, it is the first dopamine D1 receptor agonist to demonstrate a full antiparkinsonian effect in patients with Parkinson's disease. " 06/01/1999 - "Subjects (n = 14) with levodopa-responsive Parkinson's disease received five doses of ABT-431 (5, 10, 20, 30, and 40 mg) and one of placebo after a 12-hour levodopa holiday. " 06/01/1999 - "ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease." 01/01/1996 - "An agent such as A-86929 (or its prodrug ABT-431), which selectively stimulates the D1 receptor, may represent a novel mechanism for Parkinson's disease therapy with the potential for an improved side-effect profile and, consequently, improved patient compliance."
2.	Dyskinesias (Dyskinesia) 06/01/1999 - "Dyskinesia was reduced in several patients after receiving ABT-431. " 02/01/2001 - "At the most effective doses (20 and 40 mg), ABT-431 exhibited similar antiparkinsonian benefit and produced similar dyskinesias as levodopa. " 02/01/2001 - "We studied ABT-431, the prodrug of a fully selective D(1) agonist, in 20 subjects with advanced Parkinson disease and a fluctuating response to levodopa complicated by dyskinesias. " 02/01/2001 - "Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease."
3.	Cocaine-Related Disorders (Cocaine Addiction) 01/01/2000 - "The profile of ABT-431 is similar to the behavioral effects of other structurally distinct D1 agonists, and is consistent with the desired profile of a "methadone-like" compounds for cocaine addiction."
4.	Seizures (Absence Seizure) 12/19/1996 - "Young rats (35-37 days) exhibited behavioral seizures following A-86929 and ABT-431 treatment (ED50 = 34.2 and 35.6 mumol/kg, s.c., respectively), but at doses higher than those required in mice. " 12/19/1996 - "Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431."

Related Drugs and Biologics

1.	Prodrugs
2.	A 86929
3.	Dopamine D1 Receptors (Dopamine D1 Receptor)
4.	Levodopa (L Dopa)
5.	Methadone (Dolophine)
6.	Diacetyl (Biacetyl)

Related Therapies and Procedures

1.	Therapeutics